$TELO
Telomir Pharmaceuticals Inc

2024 Q2 Form 10-Q Financial Statement

#000149315224018909 Filed on May 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $879.7K $1.112M $874.8K
YoY Change 15.95% 2510.42% 8826.94%
% of Gross Profit
Research & Development $594.8K $804.0K $203.8K
YoY Change -10.9% 82.59% -57.31%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.474M $1.916M $1.079M
YoY Change 3.38% 296.75% 121.44%
Operating Profit
YoY Change
Interest Expense $25.49K $4.339M -$761.8K
YoY Change -120.56%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.449M -$6.255M -$9.327M
YoY Change -6.54% 1195.22% 1814.85%
Income Tax
% Of Pretax Income
Net Earnings -$1.449M -$6.255M -$9.327M
YoY Change -6.54% 1195.12% 1814.85%
Net Earnings / Revenue
Basic Earnings Per Share -$0.05 -$0.23
Diluted Earnings Per Share -$0.05 -$0.23 -$0.35
COMMON SHARES
Basic Shares Outstanding 29.61M shares 27.77M shares
Diluted Shares Outstanding 29.61M shares 27.77M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.884M $3.274M $1.230K
YoY Change 12803.49%
Cash & Equivalents $1.884M $3.274M $1.231K
Short-Term Investments
Other Short-Term Assets $87.81K $98.81K $304.0K
YoY Change 7.87%
Inventory
Prepaid Expenses $87.81K $98.81K $713.00
Receivables
Other Receivables
Total Short-Term Assets $2.102M $3.503M $435.2K
YoY Change 2087.02% 793.14%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $4.339M
YoY Change -100.0%
Total Long-Term Assets $0.00 $0.00 $4.339M
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $2.102M $3.503M $435.2K
Total Long-Term Assets $0.00 $0.00 $4.339M
Total Assets $2.102M $3.503M $4.774M
YoY Change -64.51% 9696.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $393.8K $221.6K $707.2K
YoY Change -74.5%
Accrued Expenses $7.360K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $101.0K
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $534.2K $486.6K $1.336M
YoY Change -73.72% 35.45%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $534.2K $486.6K $1.336M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $534.2K $486.6K $1.336M
YoY Change -73.72% 35.45%
SHAREHOLDERS EQUITY
Retained Earnings -$21.77M -$20.32M -$14.06M
YoY Change 1317.36%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.568M $3.000M $3.400M
YoY Change
Total Liabilities & Shareholders Equity $2.102M $3.503M $4.774M
YoY Change -64.51% 9696.36%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$1.449M -$6.255M -$9.327M
YoY Change -6.54% 1195.12% 1814.85%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.523M -$1.900M -$1.087M
YoY Change 97.95% 158.24% 325.02%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.833M
YoY Change 483.3%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 132.4K $5.212M 1.086M
YoY Change -83.07% 608.1% 332.85%
NET CHANGE
Cash From Operating Activities -1.523M -$1.900M -1.087M
Cash From Investing Activities
Cash From Financing Activities 132.4K $5.212M 1.086M
Net Change In Cash -1.390M $3.273M -1.190K
YoY Change -10633.33% 843478.09% -75.71%
FREE CASH FLOW
Cash From Operating Activities -$1.523M -$1.900M -$1.087M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
usd
CY2024Q1 us-gaap Deferred Costs
DeferredCosts
usd
CY2024Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
usd
CY2023Q1 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
usd
CY2023Q4 TELO Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
usd
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
CY2023Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2024Q1 TELO Accrued Offering Expense
AccruedOfferingExpense
usd
CY2023Q1 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
usd
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
usd
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-41765
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Telomir Pharmaceuticals, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-2606031
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
855 N Wolfe Street
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 601
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Baltimore
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
21205
CY2024Q1 dei City Area Code
CityAreaCode
(813)
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
864-2558
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, no par value
CY2024Q1 dei Trading Symbol
TradingSymbol
TELO
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29609814 shares
CY2023Q4 us-gaap Cash
Cash
1231 usd
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
303281 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
713 usd
CY2023Q4 us-gaap Other Receivables
OtherReceivables
130000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
435225 usd
CY2023Q4 us-gaap Deferred Costs
DeferredCosts
4338543 usd
CY2023Q4 us-gaap Assets
Assets
4773768 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
707187 usd
CY2023Q4 us-gaap Other Liabilities
OtherLiabilities
527377 usd
CY2023Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
101000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1335564 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1335564 usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29609814 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29609814 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28609814 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28609814 shares
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
17502346 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14064142 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3438204 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4773768 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
741541 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
42603 usd
CY2024Q1 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
370500 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
804023 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
440335 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
1916064 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
482938 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
4338543 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6254607 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-482938 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27768156 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27768156 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26893014 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26893014 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-937278 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
910000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-482938 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-510216 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-510216 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
5950000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1550385 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3889399 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3889399 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1711326 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2178073 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2178073 usd
CY2023Q4 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
10587346 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-9327215 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3438204 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5832973 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6254607 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3016570 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3016570 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6254607 usd
CY2024Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
4338543 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
74744 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-252801 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
98095 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1939415 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-735739 usd
CY2024Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
101000 usd
CY2024Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
519475 usd
CY2023Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
263873 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5832973 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1000000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5212498 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
736127 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3273083 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
388 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1231 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3274314 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1807 usd
CY2023Q1 TELO Accrued Offering Expense
AccruedOfferingExpense
118944 usd
CY2023Q1 us-gaap Payments For Fees
PaymentsForFees
100000 usd
CY2023Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-2.05
CY2024Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P12M
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zXWdUkBT1W6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with generally accepted accounting principles in the United States of America requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from such estimates and such differences could be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1 us-gaap Cash
Cash
3300000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1900000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3000000.0 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3400000 usd
CY2024Q1 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
221559 usd
CY2023Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
474585 usd
CY2024Q1 TELO Preclinical Research And Development
PreclinicalResearchAndDevelopment
249733 usd
CY2023Q4 TELO Preclinical Research And Development
PreclinicalResearchAndDevelopment
202998 usd
CY2024Q1 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
7358 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
29604 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
478650 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
707187 usd
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
8000.000 usd
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
500000 usd
CY2023Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-2.05
CY2024Q1 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
400000 usd
CY2024Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P12M
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
53819 usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
3708 usd
CY2024Q1 us-gaap Variable Lease Cost
VariableLeaseCost
326501 usd
CY2024Q1 us-gaap Lease Cost
LeaseCost
380320 usd
CY2023Q1 us-gaap Lease Cost
LeaseCost
3708 usd
CY2024Q1 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
400000000 shares
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-2.05
CY2023Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-2.05
CY2023Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-2.05
CY2023 TELO Deferred Finance Costs
DeferredFinanceCosts
5950000 usd
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.00
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2168086 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39088 shares

Files In Submission

Name View Source Status
0001493152-24-018909-index-headers.html Edgar Link pending
0001493152-24-018909-index.html Edgar Link pending
0001493152-24-018909.txt Edgar Link pending
0001493152-24-018909-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
telo-20240331.xsd Edgar Link pending
telo-20240331_cal.xml Edgar Link unprocessable
telo-20240331_lab.xml Edgar Link unprocessable
telo-20240331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
telo-20240331_def.xml Edgar Link unprocessable